bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.07.21.665961

Strong GAL4 expression compromises Drosophila fat body function

Abstract

The ability to direct tissue-specific overexpression of transgenic proteins in genetically tractable organisms like Drosophila melanogaster has facilitated innumerable biological discoveries. However, transgenic proteins can themselves impact cellular and physiological processes in ways that are often ignored or poorly defined. Here we discovered that the yolk-GAL4 transgene, which directs strong expression of the yeast GAL4 transcription factor in the Drosophila fat body, induces significant physiological defects in adult female flies. We found that yolk-GAL4 disrupts adipose tissue integrity and reduces fat body lipid stores, egg production, and resistance to systemic bacterial infections. Knocking down GAL4 expression in yolk-GAL4 heterozygotes using RNAi fully suppressed each of these defects, thus confirming that the GAL4 transgene product induces these phenotypes. Comparing a panel of additional fat body driver lines, we found that GAL4 expression levels directly correlate infection susceptibility, but not with fat levels or egg production. To determine whether other transgenic proteins can impair fat body function, we constructed new fly lines in which the yolk enhancer directs expression of either cytoplasmic or nuclear-localized mCherry, or an alternative transactivator, LexA. We found that only nuclear-localized mCherry and LexA increased infection susceptibility similarly to GAL4, suggesting that intranuclear transgenic proteins in general can curtail the fat bodys induced immune response in a manner highly sensitive to transgene expression strength. Additionally, these new lines can be valuable tools for future studies. More broadly, our findings highlight the potential for transgenes to substantially impact organismal biology and emphasize the importance of rigorously characterizing genetic tools to optimally leverage model systems like Drosophila.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Keith, S. A., Kalukin, A. A., Vargas Solivan, D. S., Smee, M. R., Lazzaro, B. P.. 2025-07-24. Strong GAL4 expression compromises Drosophila fat body function. https://doi.org/10.1101/2025.07.21.665961

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗